ES2680820T3 - Derivados de azaspiro(4,5)decano sustituidos - Google Patents

Derivados de azaspiro(4,5)decano sustituidos Download PDF

Info

Publication number
ES2680820T3
ES2680820T3 ES15737988T ES15737988T ES2680820T3 ES 2680820 T3 ES2680820 T3 ES 2680820T3 ES 15737988 T ES15737988 T ES 15737988T ES 15737988 T ES15737988 T ES 15737988T ES 2680820 T3 ES2680820 T3 ES 2680820T3
Authority
ES
Spain
Prior art keywords
nhc
nhr0
aliphatic
aryl
polysubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15737988T
Other languages
English (en)
Inventor
Anita Wegert
Bert Nolte
Klaus Linz
Stephanie Harlfinger
Babette-Yvonne Kögel
Paul Ratcliffe
Fritz Theil
Olga GRÖGER
Birgit Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2680820T3 publication Critical patent/ES2680820T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la fórmula general (1)**Fórmula** donde Y1, Y1', Y2, Y2', Y3, Y3', Y4 e Y4' en cada caso se eligen independientemente entre sí de entre el grupo que consiste en -H, -F, -Cl, -Br, -I, -CN, -NO2, -CHO, -R0, -C(>=O)R0, -C(>=O)H, -C(>=O)-OH, -C(>=O)OR0, -C(>=O)NH2, -C(>=O)NHR0, - C(>=O)N(R0)2, -OH, -OR0, -OC(>=O)H, -OC(>=O)R0, -OC(>=O)OR0, -OC(>=O)NHR0, -OC(>=O)N(R0)2, -SH, -SR0, -SO3H, - S(>=O)1-2-R0, -S(>=O)1-2NH2, -NH2, -NHR0, -N(R0)2, -N+(R0)3, -N+(R0)2O-, -NHC(>=O)R0, -NHC(>=O)OR0, -NHC(>=O)NH2, - NHC(>=O)NHR0 y -NHC(>=O)N(R0)2; o Y1 e Y1', o Y2 e Y2', o Y3 e Y3', o Y4 e Y4' representan conjuntamente >=O; X1, X1', X2, X2', X3 y X3' en cada caso representan independientemente entre sí -H, -F, -Cl, -Br, -I, -NO2, -CF3, -OR5, - SR5, -SO2R5, -S(>=O)2OR5, -CN, -COOR5, -CONR5, -NR6R7, o -R0; o X1 y X1', o X2 y X2', o X3 y X3' representan conjuntamente >=O; o X1 y X2, o X2 y X3 representan conjuntamente -(CH2)2-6-, donde los átomos de hidrógeno individuales también pueden estar sustituidos por -F, -Cl, -Br, -I, -NO2, -CF3, -OR5, -CN o -C1-6-alifático; o X1 y X1', o X2 y X2' o X3 y X3' representan conjuntamente un C3-6-cicloalifático, donde los átomos de hidrógeno individuales también pueden estar sustituidos por -F, -Cl, -Br, -I, -NO2, -CF3, -OR5, -CN o -C1-6-alifático; R0 en cada caso representa independientemente -C1-8-alifático, -C3-12-cicloalifático, -arilo, -heteroarilo, -C1-8-alifático- C3-12-cicloalifático, -C1-8-alifático-arilo, -C1-8-alifático-heteroarilo, -C3-8-cicloalifático-C1-8-alifático, -C3-8-cicloalifáticoarilo o -C3-8-cicloalifático-heteroarilo; R1 y R2 representan independientemente entre sí -H o -R0; o R1 y R2 representan conjuntamente -CH2CH2OCH2CH2- , -CH2CH2NR8CH2CH2- o -(CH2)3-6-; R3 representa -R0; R4 representa H o -Z-R11, donde Z puede estar ausente o -C(>=O)-, -S(>=O)- o -S(>=O)2-, y R11 representa -C1-6-alquilo, -C3-6-cicloalquilo o -C1-3-alquil-C3-6-cicloalquilo, donde en el grupo C3-6-cicloalquilo un átomo de carbono del anillo puede estar sustituido por un átomo de oxígeno y -C1-6-alquilo, -C3-6-cicloalquilo o -C1-3- alquil-C3-6-cicloalquilo puede estar no sustituido, monosustituido o polisustituido con sustituyentes seleccionados de entre el grupo que consiste en -F, -Cl, -Br, -I, -CN, -OH, -SH, -O-C1-3-alquilo y -S-C1-3-alquilo, donde -C1-3-alquilo puede estar sustituido por uno o más sustituyentes de entre el grupo que incluye los sustituyentes -F, -Cl, -Br, - I, -CN, -OH, -SH; R5 en cada caso representa independientemente -H o -R0; R6 y R7 representan independientemente entre sí -H o -R0; o R6 y R7 representan conjuntamente -CH2CH2OCH2CH2- , -CH2CH2NR10CH2CH2- o -(CH2)3-6-; R8 representa -H, -R0 o -C(>=O)R0; R10 representa -H o -C1-6-alifático; donde "alifático" es en cada caso un radical de hidrocarburo alifático, ramificado o no ramificado, saturado o monoinsaturado o poliinsaturado, no sustituido o monosustituido o polisustituido; "cicloalifático" es en cada caso un radical de hidrocarburo saturado o monoinsaturado o poliinsaturado, no sustituido o monosustituido o polisustituido, alicíclico, monocíclico o multicíclico; donde con respecto a "alifático" y "cicloalifático", se entiende que "monosustituido o polisustituido" significa la sustitución de uno o más átomos de hidrógeno por -F, -Cl, -Br, -I, -CN, -NO2, -CHO, >=O, -R0, -C(>=O)R0, -C(>=O)H, - C(>=O)-OH, -C(>=O)OR0, -C(>=O)NH2, -C(>=O)NHR0, -C(>=O)N(R0)2, -OH, -OR0, -OC(>=O)H, -OC(>=O)R0, - OC(>=O)OR0, -OC(>=O)NHR0, -OC(>=O)N(R0)2, -SH, -SR0, -SO3H, -S(>=O)1-2-R0, -S(>=O)1-2NH2, -NH2, -NHR0, -N(R0)2, - N+(R0)3, -N+(R0)2O-, -NHC(>=O)R0, -NHC(>=O)OR0, -NHC(>=O)NH2, -NHC(>=O)NHR0, -NH-C(>=O)N(R0)2, -Si(R0)3, - PO(OR0)2; "arilo" en cada caso representa independientemente un sistema de anillo carbocíclico que tiene al menos un anillo aromático, pero sin heteroátomos en este anillo, donde los radicales arilo pueden estar fusionados opcionalmente con sistemas de anillos adicionales saturados, (parcialmente) insaturados o aromáticos y cada radical arilo puede estar no sustituido o monosustituido o polisustituido, donde los sustituyentes en el arilo pueden ser idénticos o diferentes y pueden estar en cualquier posición deseada y posible del arilo; "heteroarilo" representa un radical aromático cíclico de 5, 6 o 7 miembros que contiene 1, 2, 3, 4 o 5 heteroátomos, donde los heteroátomos son idénticos o diferentes y son nitrógeno, oxígeno o azufre y el heterociclo puede estar no sustituido o monosustituido o polisustituido; donde en el caso de sustitución en el heterociclo los sustituyentes pueden ser idénticos o diferentes y pueden estar en cualquier posición deseada y posible del heteroarilo; y donde el heterociclo puede también formar parte de un sistema bicíclico o policíclico; donde con respecto a "arilo" y "heteroarilo", se entiende que "monosustituido o polisustituido" significa la sustitución una o varias veces de uno o más átomos de hidrógeno del sistema del anillo por sustituyentes elegidos de entre el grupo que consiste en -F, -Cl, -Br, -I, -CN, -NO2, -CHO, >=O, -R0, -C(>=O)R0, -C(>=O)H, -C(>=O)OH, -C(>=O)OR0, - C(>=O)NH2, -C(>=O)NHR0, -C(>=O)-N(R0)2, -OH, -O(CH2)1-2O-, -OR0, -OC(>=O)H, - OC(>=O)R0, -OC(>=O)OR0, -OC(>=O)NHR0, -OC(>=O)N(R0)2, -SH, -SR0, -SO3H, -S(>=O)1-2-R0, -S(>=O)1-2NH2, - NH2, -NHR0, -N(R0)2, -N+(R0)3, -N+(R0)2O-, -NHC(>=O)R0, -NHC(>=O)OR0, -NH-C(>=O)NH2, -NHC(>=O)NHR0, - NHC(>=O)N(R0)2, -Si(R0)3, -PO(OR0)2; donde N átomos del anillo presentes opcionalmente pueden estar en cada caso oxidados (N-óxido); en forma de un estereoisómero individual o mezcla del mismo, el compuesto libre y/o su sal y/o solvato fisiológicamente aceptable.
ES15737988T 2014-07-15 2015-07-14 Derivados de azaspiro(4,5)decano sustituidos Active ES2680820T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14002438 2014-07-15
PCT/EP2015/001446 WO2016008583A1 (de) 2014-07-15 2015-07-14 Substituierte aza-spiro(4.5)decan-derivate

Publications (1)

Publication Number Publication Date
ES2680820T3 true ES2680820T3 (es) 2018-09-11

Family

ID=51211483

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15737988T Active ES2680820T3 (es) 2014-07-15 2015-07-14 Derivados de azaspiro(4,5)decano sustituidos

Country Status (22)

Country Link
US (1) US10202345B2 (es)
EP (1) EP3169665B1 (es)
JP (1) JP6490187B2 (es)
CN (1) CN106536514A (es)
AU (1) AU2015291468B2 (es)
BR (1) BR112017000766A2 (es)
CA (1) CA2955073A1 (es)
CY (1) CY1120443T1 (es)
DK (1) DK3169665T3 (es)
EA (1) EA201790186A1 (es)
ES (1) ES2680820T3 (es)
HR (1) HRP20180940T1 (es)
HU (1) HUE039604T2 (es)
LT (1) LT3169665T (es)
MX (1) MX2017000519A (es)
PL (1) PL3169665T3 (es)
PT (1) PT3169665T (es)
RS (1) RS57388B1 (es)
SI (1) SI3169665T1 (es)
TR (1) TR201809663T4 (es)
TW (1) TW201607923A (es)
WO (1) WO2016008583A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790185A1 (ru) * 2014-07-15 2017-07-31 Грюненталь Гмбх Замещенные азаспиро(4.5)декановые производные
WO2019152688A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA827340B (en) * 1981-11-12 1983-10-26 Upjohn Co Analgesic 1-oxa-,aza-and thia-spirocyclic compounds
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TR200001256T2 (tr) 1997-11-04 2000-11-21 Pfizer Products Inc. Terapötik olarak aktif bileşimler.
ES2185591T3 (es) * 1999-06-02 2003-05-01 Warner Lambert Co Amino hererociclos utiles como agentes farmaceuticos.
HUP9902374A3 (en) 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1266112C (zh) 2001-04-24 2006-07-26 麻省理工学院 铜－催化的碳－杂原子键和碳－碳键的形成
DE10210190A1 (de) * 2002-03-07 2003-09-25 Sanol Arznei Schwarz Gmbh Aza-Spiroverbindungen
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ATE464305T1 (de) 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
WO2006034110A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (arylamidoaryl) cyanoguanidine compounds as inhibitors of c-kit proto-oncogene
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EP1981854B1 (en) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
DE102005061428A1 (de) 2005-12-22 2007-08-16 Grünenthal GmbH Substituierte Cyclohexylmethyl-Derivate
ATE471311T1 (de) 2006-04-25 2010-07-15 Lilly Co Eli Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006033114A1 (de) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
EP2066674B1 (en) 2006-09-18 2010-06-30 F.Hoffmann-La Roche Ag Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents
PL2078022T3 (pl) 2006-09-22 2012-04-30 Janssen Pharmaceutica Nv Spirobenzoazepiny stosowane jako antagoniści wazopresyny
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
MX2009009355A (es) 2007-03-01 2009-09-11 Mitsubishi Tanabe Pharma Corp Compuesto de bencimidazol y uso farmaceutico del mismo.
GB0707934D0 (en) 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
CA2719743A1 (en) 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted cyclohexyldiamines
CA2719736C (en) * 2008-03-27 2016-02-09 Gruenenthal Gmbh Spiro(5.5)undecane derivatives
KR20120075500A (ko) * 2008-03-27 2012-07-06 그뤼넨탈 게엠베하 치환된 4-아미노사이클로헥산 유도체
WO2009118173A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte spirocyclische cyclohexan-derivate
AR073841A1 (es) 2008-03-27 2010-12-09 Gruenenthal Chemie Hidroximetilciclohexilaminas, medicamentos y uso de los mismos para la fabricacion de medicamentos.
UA104004C2 (uk) 2008-07-30 2013-12-25 Пердью Фарма Л.П. Аналоги бупренорфіну
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
GB201111775D0 (en) 2011-07-08 2011-08-24 Univ Bath Compounds and uses thereof
CN107266345B (zh) * 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物

Also Published As

Publication number Publication date
LT3169665T (lt) 2018-07-10
PL3169665T3 (pl) 2018-12-31
JP6490187B2 (ja) 2019-03-27
TR201809663T4 (tr) 2018-07-23
HUE039604T2 (hu) 2019-01-28
HRP20180940T1 (hr) 2018-07-27
SI3169665T1 (en) 2018-08-31
MX2017000519A (es) 2017-05-01
BR112017000766A2 (pt) 2017-11-21
US20160016903A1 (en) 2016-01-21
US10202345B2 (en) 2019-02-12
AU2015291468B2 (en) 2019-01-24
EP3169665A1 (de) 2017-05-24
PT3169665T (pt) 2018-07-12
AU2015291468A1 (en) 2017-03-02
TW201607923A (zh) 2016-03-01
CN106536514A (zh) 2017-03-22
CA2955073A1 (en) 2016-01-21
EA201790186A1 (ru) 2017-07-31
DK3169665T3 (en) 2018-06-25
EP3169665B1 (de) 2018-05-09
WO2016008583A1 (de) 2016-01-21
JP2017520599A (ja) 2017-07-27
RS57388B1 (sr) 2018-09-28
WO2016008583A8 (de) 2016-03-31
CY1120443T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
AR071068A1 (es) Derivados de ciclohexano espirociclicos sustituidos
AR134548A2 (es) Compuesto esteroide neuroactivo
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
CL2020001546A1 (es) Compuestos de 4-azaindol.
PE20180949A1 (es) Nuevos derivados hidroxiacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
IL262030B (en) Silicone atoms containing ivacaftor analogues
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
AR099994A1 (es) Compuesto de ciclopropanamina y sus usos
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CU24448B1 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
PE20160167A1 (es) Composiciones y metodos para alterar la senalizacion del segundo mensajero
MX2018004743A (es) Deshidratacion compacta submarina.
ES2686326T3 (es) Derivados de azaspiro(4,5)decano sustituidos
CO6700838A2 (es) Compuestos sustituidos de banzamida
BR112019002881A2 (pt) aparelho e sistema para processos aprimorados de remoção de contaminante seletivo relacionados aos mesmos
IN2014DN09291A (es)
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
PE20180327A1 (es) Proceso para preparar 4-amino-piridazinas
BR112017025946A8 (pt) Método para purificar biogás e sistema de purificação de biogás
MX381562B (es) Proceso para aislar y purificar ambrox.
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
MX2022009886A (es) Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
AR101317A1 (es) Moléculas que poseen ciertas utilidades plaguicidas, intermediarios, composiciones y procesos relacionados con dichas moléculas